Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of August 2025, with the report dated August 14, 2025. The filing addresses a regulatory compliance matter regarding the company's continued listing on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the company's stockholders' equity status relative to Nasdaq listing requirements.
Material Changes and Regulatory Status
- Nasdaq Deficiency: On April 15, 2025, the company received notification that it failed to comply with Nasdaq Listing Rule 5550(b), which mandates a minimum stockholders' equity of $2,500,000.
- Compliance Extension: On August 8, 2025, Nasdaq granted an extension allowing the company until October 13, 2025, to regain compliance.
- Plan Submission: The company has submitted a plan to Nasdaq detailing how it intends to meet the equity requirement.
Outlook, Risks, and Contingencies
Future Actions: If the company fails to regain compliance by October 13, 2025, it may appeal the determination to a Hearings Panel. An accepted appeal would provide additional time to achieve compliance.
Risks and Uncertainties: The filing includes a special note on forward-looking statements, highlighting that actual results may differ materially from expectations. Key risks include market conditions and the satisfaction of conditions necessary to close financing arrangements required to restore equity levels.
Investor Verification Checklist
- Verify the company's current stockholders' equity balance to assess the gap against the $2,500,000 threshold.
- Review the specific financing arrangements or capital raise plans submitted to Nasdaq to determine feasibility.
- Monitor the status of the October 13, 2025, compliance deadline and any potential appeal to the Hearings Panel.
- Check subsequent filings for updates on the execution of the compliance plan.